A recent study found that only 12% of patients older than 80 years received radical treatment for invasive disease.
A pathologist was unable to determine if a bladder tumor was muscle invasive because biopsy samples did not include muscle tissue.
Radical cystectomy with urinary diversion including neobladder remains the standard of care for muscle-invasive bladder cancer.
Intravesical chemotherapy right after transurethral resection of bladder tumor prolonged the recurrence-free interval by 38%.
Routine screening for bladder cancer may be warranted in this patient population.
Increased prophylaxis may benefit patients with non-O blood type.
Lower urinary tract symptoms alone should raise suspicion for the malignancy.
Compared with non-smokers, heavy smokers had a 38% increased risk of having muscle-invasive disease at presentation.
A large observational study showed that cannabis users had a 45% decreased risk of developing the malignancy.
Study reveals no decrease in death risk associated with perioperative and early follow-up care.
Patients aged 75 and older had longer stays in the intensive care unit and higher complication rates.
Patients undergoing radical cystectomy for bladder cancer may be at increased risk for worse outcomes if they receive a PBT.
Authors suggest that guidelines should be revised to exclude routine urine cytology
Rate of 10 conditions considered to be reasonably preventable 2.42% after radical cystectomy.
Quantity, duration, and cumulative exposure is tied to recurrence, mortality for females.
SNPs in G-protein signal pathway regulator tied to overall risk, recurrence, progression, death.
In patients with muscle-invasive bladder cancer, those with bladder neck or multiple tumors are more likely to experience recurrent intravesical tumors.
Only 12% of patients older than 80 years received radical treatment for invasive disease compared with 52% of those younger than 60 years.